Novel orally active renin inhibitors, including A-72517, were developed and demonstrated high bioavailability and efficacy in animal models.
Answers are grounded in this paper and cite their sources.
Supports advancement of oral renin inhibitors to human testing; leaves open demonstration of clinical efficacy and safety.
Employing a set of empirical guidelines for the design of well-absorbed renin inhibitors, we have followed two strategies to improve potency while maintaining bioavailability. One process involved incorporation of an extended N-terminal residue bearing a weakly basic substituent and is exemplified by compound 25. The other approach centered on the inclusion of an N-terminal sulfonamide and culminated in the discovery of inhibitor 32 (A-72517). Both 25 and 32 showed excellent bioavailability in the rat and ferret (> 25%) and, while subject to hepatic elimination in the monkey, were efficacious in this species.
No takes yet. Share an insight, caveat, or question.
Rosenberg et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: